(Q38224988)

31 August 2017

title

Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia (English)

1 reference

31 August 2017

1 reference

Caroline Le Jeune

1

1 reference

31 August 2017

Xavier Thomas

series ordinal

2

1 reference

31 August 2017

publication date

18 August 2014

1 reference

European Journal of Haematology

31 August 2017

published in

1 reference

31 August 2017

volume

94

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

99-108

1 reference

Adult acute lymphoblastic leukemia: concepts and strategies

31 August 2017

cites work

1 reference

Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission

21 January 2018

1 reference

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

21 January 2018

1 reference

Modern therapy of acute lymphoblastic leukemia

21 January 2018

1 reference

Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing

21 January 2018

1 reference

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

21 January 2018

1 reference

Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects

21 January 2018

1 reference

Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

Novel antibody-based therapies for acute lymphoblastic leukemia

21 January 2018

1 reference

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

21 January 2018

1 reference

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

21 January 2018

1 reference

Rituximab: mechanism of action and resistance

21 January 2018

1 reference

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

Molecular diagnosis of Burkitt's lymphoma

21 January 2018

1 reference

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.

21 January 2018

1 reference

High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults

21 January 2018

1 reference

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

21 January 2018

1 reference

Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia

21 January 2018

1 reference

Chemoimmunotherapy in acute lymphoblastic leukemia

21 January 2018

1 reference

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

The late adverse events of rituximab therapy--rare but there!

21 January 2018

1 reference

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.

21 January 2018

1 reference

Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention

21 January 2018

1 reference

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

21 January 2018

1 reference

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

21 January 2018

1 reference

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

21 January 2018

1 reference

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

21 January 2018

1 reference

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

21 January 2018

1 reference

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies

21 January 2018

1 reference

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

21 January 2018

1 reference

Cellular therapies in acute lymphoblastic leukemia

21 January 2018

1 reference

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

21 January 2018

1 reference

Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies

21 January 2018

1 reference

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study

21 January 2018

1 reference

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

21 January 2018

1 reference

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

21 January 2018

1 reference

BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle

21 January 2018

1 reference

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

21 January 2018

1 reference

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

21 January 2018

1 reference

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates

21 January 2018

1 reference

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

21 January 2018

1 reference

Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia

21 January 2018

1 reference

A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

21 January 2018

1 reference

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report

21 January 2018

1 reference

Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.

21 January 2018

1 reference

Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EJH.12408

1 reference

31 August 2017

1 reference